A Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia., Trial ID 2215-CL-0104

Study summary

The purpose of phase 1 part in this study is to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase 1 part will also evaluate safety and tolerability and characterize the pharmacokinetic (PK) parameters of ASP2215 concomitant with induction and consolidation chemotherapy as well as evaluate the PK parameters of cytarabine concomitant with ASP2215.

The purpose of phase 2 part is to evaluate efficacy of ASP2215 in combination with induction therapy. Phase 2 cohort will also evaluate safety and characterize the PK parameters of ASP2215 in combination with induction and consolidation therapy followed by maintenance therapy in newly diagnosed FLT3-mutated AML subjects.

Additional Study Details

Phase

Phase 1/Phase 2

Product

ASP2215

Product

gilteritinib

Idarubicin

Cytarabine

Type

Interventional

Masking

None (Open Label)

Enrollment number

Show Additional Study Details

Study documents

Plain Language Summary

Available Language(s): English, English

Download Document(s)

Protocol

Available Language(s): English, English

Download Document(s)

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.? Contact us by filling out your information to the right and we’ll respond to you.

Requestor Information [I am…]

A caregiver
A healthcare provider
A parent
A patient
A patient advocate

First name

Last Name

Country/Region

Algeria
Argentina
Armenia
Australia
Austria
Belarus
Belgium
Bosnia And Herzegovina
Brazil
Bulgaria
Canada
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Dominican Republic
Egypt
Estonia
Finland
Former Serbia and Montenegro
France
Georgia
Germany
Greece
Guatemala
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Latvia
Lebanon
Lithuania
Macedonia
Malaysia
Mexico
Montenegro
Morocco
Netherlands
New Zealand
Norway
Panama
Peru
Philippines
Poland
Portugal
Puerto Rico
Republic of Korea
Republic of Moldova
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Taiwan, Province of China
Thailand
Turkey
Ukraine
United Kingdom
United States
Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

I give my consent to the processing of my personal data mentioned above according to Astellas Privacy Notice & Cookies Policy

Locations

Recruiting

Site JP81035

Sendai, Miyagi, Japan

Recruiting

Site JP81013

Isehara, Kanagawa, Japan

Recruiting

Site JP81008

Chiba, Chiba, Japan

Recruiting

Site JP81037

Anjo, Aichi, Japan

Completed

Site JP00001

Fukuoka, Fukuoka, Japan

Recruiting

Site JP81029

Akita, Akita, Japan

Recruiting

Site TW88604

Kaohsiung, Taiwan, Province of China

Recruiting

Site JP81023

Tsukuba, Ibaraki, Japan

Recruiting

Site JP81038

Toyohashi, Aichi, Japan

Recruiting

Site JP81001

Maebshi, Gunma, Japan

Recruiting

Site JP81009

Okayama, Okayama, Japan

Recruiting

Site JP81028

Kumamoto, Kumamoto, Japan

Recruiting

Site JP81032

Shinagawa-ku, Tokyo, Japan

Recruiting

Site JP81016

Kyoto, Kyoto, Japan

Recruiting

Site JP81019

Osaka, Osaka, Japan

Recruiting

Site KR82002

Incheon, Republic of Korea

Completed

Site JP00006

Yokohama, Kanagawa, Japan

Recruiting

Site JP81030

Gifu, Gifu, Japan

Recruiting

Site JP81003

Nagoya, Aichi, Japan

Recruiting

Site KR82006

seoul, Republic of Korea

Recruiting

Site JP81020

Kanazawa, Ishikawa, Japan

Recruiting

Site JP81012

Nagasaki, Nagasaki, Japan

Recruiting

Site JP81018

Otake, Hiroshima, Japan

Recruiting

Site JP81002

Shinagawa-ku, Tokyo, Japan

Recruiting

Site JP81036

Mito, Ibaraki, Japan

Recruiting

Site JP81007

Yoshida-gun, Fukui, Japan

Recruiting

Site TW88602

Taichung, Taiwan, Province of China

Recruiting

Site JP81040

Bunkyo-ku, Tokyo, Japan

Recruiting

Site JP81041

Tenri, Nara, Japan

Recruiting

Site TW88603

Taoyuan, Taiwan, Province of China

Recruiting

Site JP81022

Shimono, Tochigi, Japan

Recruiting

Site JP81004

Fukuoka, Fukuoka, Japan

Recruiting

Site KR82005

Seoul, Republic of Korea

Recruiting

Site JP81027

Nagoya, Aichi, Japan

Recruiting

Site KR82004

Seoul, Republic of Korea

Recruiting

SIte JP81011

Omura, Nagasaki, Japan

Recruiting

Site JP81033

Kochi, Kochi, Japan

Recruiting

Site JP81039

Matsuyama, Ehime, Japan

Recruiting

Site JP81025

Fukuoka, Fukuoka, Japan

Recruiting

Site JP81024

Yokohama, Kanagawa, Japan

Recruiting

Site KR82001

Seoul, Republic of Korea

Recruiting

Site JP81021

Osaka, Osaka, Japan

Recruiting

Site JP81026

Fukuyama, Hiroshima, Japan

Recruiting

Site JP81031

Fukushima, Fukushima, Japan

Completed

Site JP00007

Kobe, Hyogo, Japan

Recruiting

Site JP81017

Nakagyo-ku, Kyoto, Japan

Completed

Site JP00005

Shinagawa-ku, Tokyo, Japan

Completed

Site JP00002

Maebashi, Gunma, Japan

Recruiting

Site JP81005

Yokohama, Kanagawa, Japan

Recruiting

Site TW88601

Tainan, Taiwan, Province of China

Recruiting

Site KR82003

Seoul, Republic of Korea

Recruiting

Site JP81015

Sapporo, Hokkaido, Japan

Recruiting

Site JP81014

Sapporo, Hokkaido, Japan

Recruiting

Site JP81006

Kobe, Hyogo, Japan

Recruiting

Site JP81010

Narita, Chiba, Japan

Completed

Site JP00003

Nagoya, Aichi, Japan

Recruiting

Site JP81034

Suwa, Nagano, Japan

Recruiting

Site JP81043

Himeji, Hyogo, Japan

Trial info

Follow Trial

Age

18 - 69 years

Condition

Leukemia - AML

Sex

Female & Male

Trial Dates

Feb 2015 - Sep 2021

Share with

Additional Study Details

Inclusion Criteria

[Phase 1 part]

Subject is defined as having previously untreated de novo AML according to the World Health Organization (WHO) criteria (2008) within 28 days prior to study enrollment.
Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Subject must meet all of the following criteria in the laboratory test at screening:
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of ≤ 2.5 × institutional upper limit of normal (ULN)
- Total serum bilirubin level of ≤ 1.5 × institutional ULN
- Serum creatinine level of ≤ 1.5 × institutional ULN or an estimated glomerular filtration rate (eGFR) of > 50 mL/min
Subject is suitable for oral administration of ASP2215.
Female subject falls under the following:
- Of non-childbearing potential:
- ・Post-menopausal (defined as at least 1 year with no menses without a medical reason such as drug administration) at screening, or
- ・Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening)
- Of childbearing potential:
- ・Has a negative result for the pregnancy test at screening, and
- ・Agrees to use an appropriate contraception starting at screening and throughout the study period and for 60 days after the final study drug administration
Female subject agrees not to breastfeed starting at screening and throughout the study period and for 60 days after the final study drug administration.
Female subject agrees not to donate ova starting at screening and throughout the study period and for 60 days after the final study drug administration.
Male subject and his female spouse/partner who is of childbearing potential agrees to use an appropriate contraception starting at screening and throughout the study period and for 120 days after the final study drug administration.
Male subject agrees not to donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
Subject agrees not to participate in another interventional study while on study treatment.
Subject can be admitted during the induction period.

[Phase 2 part]

Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to World Health Organization (WHO) classification (2017) documented within 28 days prior to enrollment.
Subject is positive for FLT3-ITD and/or TKD mutation in bone marrow or whole blood as determined by the central lab. Registration by the local lab result is not acceptable.
Subject has an ECOG performance status (PS) 0 to 1. Subject who has an ECOG PS 2 is eligible only if the primary disease related symptoms such as pneumonia and febrile neutropenia are the cause of PS score.
Subject is suitable for oral administration of ASP2215.
Female subject is not pregnant and at least 1 of the following conditions apply:
- Not a woman of childbearing potential (WOCBP)
- WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 180 days after final study treatment administration.
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
Male subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and continue throughout the study period and for 120 days after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 120 days after the final study treatment administration.
Subject agrees not to participate in another interventional study while on treatment.
Subject must meet the following criteria as indicated on the clinical laboratory tests:
- Serum creatinine ≤ 1.5 × institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 50 mL/min/1.73m^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
- Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert’s syndrome.
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN. If liver abnormality by the primary disease is suspected, subject may be pre-registered to initiate the chemotherapy. Prior to registration, AST/ALT values must meet the criteria to continue the study.
- Serum magnesium ≥ institutional lower limit of normal (LLN). Subject may pre-register without magnesium value, but subject must meet the criteria prior to the full registration on Day 8.
- Serum potassium ≥ institutional lower limit of normal (LLN).

Exclusion Criteria

[Phase 1 part]

Subject was diagnosed with acute promyelocytic leukemia (APL).
Subject has breakpoint cluster region-abelson (BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis).
Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS).
Subject has received prior AML treatment except for the following:
- Urgent leukapheresis
- Hydroxyurea administration for emergency treatment of hyperleukocytosis (≤ 7 days)
- Administration of retinoic acid before the diagnosis to exclude APL (≤ 7 days)
- Supportive care using growth factors or cytokines
- Steroid administration to treat hypersensitivity or blood transfusion reactions
Subject has clinically active central nervous system leukemia.
Subject has disseminated intravascular coagulation (DIC).
Subject has had major surgery within 28 days prior to the first study drug administration.
Subject has had radiation therapy within 28 days prior to the first study drug administration.
Subject has congestive heart failure of New York Heart Association (NYHA) class 3 or 4, or subject with a past history of congestive heart failure of NYHA class 3 or 4 and in whom echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%.
Subject has cardiac impairment or a clinically significant cardiac disease, including any one of the following:
- Complete left bundle branch block
- Obligate use of a cardiac pacemaker
- Long QT syndrome at Screening
- Prolongation of the QTc interval (> 450 ms) on electrocardiogram (ECG) at screening
- Right bundle branch block + left anterior hemiblock (bifascicular block)
- Angina pectoris within 3 months prior to study drug administration
- Acute myocardial infarction within 3 months prior to study drug administration
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
Subject requires treatment with concomitant drugs that target serotonin 5HT1 or 5HT2B receptors or sigma receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
Subject has an active uncontrollable infection.
Subject is known to have human immunodeficiency virus (HIV) infection.
Subject has active hepatitis B or C or other active hepatic disorders.
Subject has any condition that, in the investigator’s or sub-investigator’s opinion, makes the subject unsuitable for study participation.
Potassium and magnesium levels of below institutional lower limit of normal in the laboratory test at screening.

[Phase 2 part]

Subject was diagnosed with acute promyelocytic leukemia (APL).
Subject has known BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Subject has therapy-related AML.
Subject has active malignant tumors other than AML.
Subject has received previous therapy for AML, with the exception of the following:
- Emergency leukapheresis
- Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 10 days
- Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days
- Growth factor or cytokine support
- Steroids for the treatment of hypersensitivity or transfusion reactions.
Subject has QTcF interval > 450 ms (average of triplicate determinations based on central reading).
Subject with long QT syndrome.
Subject has clinically active central nervous system leukemia.
Subject has had major surgery within 4 weeks prior to the first study dose.
Subject has radiation therapy within 4 weeks prior to the first study dose.
Subject has immediate life-threatening, severe complications of leukemia such as severe uncontrolled bleeding and/or severe disseminated intravascular coagulation
Subject is known to have human immunodeficiency virus infection.
Subject has active hepatitis B or C.
Subject has an uncontrolled infection. An infection controlled with an approved or closely monitored antibiotic/antiviral/antifungal treatment is allowed.
Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure of NYHA class 3 or 4 and echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of < 45%.
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
Subject requires treatment with concomitant drugs that target serotonin 5HT2B receptors or sigma nonspecific receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.
Subject has any condition which makes the subject unsuitable for study participation.

Frequently Asked Questions

Are clinical trials only for people with advanced cancer?

While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

Will I have to stop my current treatment to participate in a clinical trial?

Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

Should I be worried about getting a placebo?

In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

Do I need a referral from my doctor to take part in a study?

Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

Explore More

A Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Study summary

Additional Study Details

Study documents

Get more information

Locations

Frequently Asked Questions

Explore More

What are clinical trials?

Why are Clinical Trials Important?

Why Participate in a Clinical Trial?